Rabies virus is accountable for substantial economic burden, and possesses high risk to the individuals living in low-income countries. Rabies is fatal encephalitis caused by the rabies virus (RABV) and usually transmit to humans through bites from rabid animals. The causative agent for this life threatening disease is RABV, containing single-stranded negative-sense RNA as genetic material (Jackson, [@B3]). Annually, rabies is responsible for approximately 55,000 deaths worldwide (a substantial part of deaths occur in developing countries); (Ge et al., [@B2]). Vaccination is the principal path for prevention and control of the disease. Currently available cell culture based rabies vaccines possess several side effects (e.g. fever, headache, neurological disease etc.) and high cost in developing countries usually require many doses to provide pre and post-exposure protection against the RABV. Several, improved vaccines based on anti-rabies monoclonal antibodies, lyophilized, and cell culture technology, are already under clinical development phase (Kaur et al., [@B4]). Furthermore, recombinant molecules have also been used as vaccine candidates very extensively. Further, immunogenicity of these molecules can be enhanced by combining adjuvants and immuno-stimulatory molecules. In the past, Wen et al. demonstrated that recombinant rabies virus (rRABV) expressing dendritic cell activating molecules such as granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage-derived chemokine (MDC), and macrophage inflammatory protein (MIP-1a), could enhance RABV immunogenicity (Wen et al., [@B9]). Moreover, Zhou et al. suggested that rRABV expressing bacterial flagellin could also induce robust adaptive immune responses (Zhou et al., [@B10]). Flagellin is a very effective and potent adjuvant because of non-inducer of IgE production and at very low dose (1--10 μg in non-human primates) very efficient to induce effective immune responses (Mizel and Bates, [@B6]). Recombinant virus-like particles (VLPs) are promising vaccine candidates, because they mimic original virus structure and are able to induce potent humoral and cellular immune responses (Kumar et al., [@B5]). Moreover, VLP possesses several advantages over the conventional vaccines because of the lack of genetic material, stable in extreme environment and capable of expressing foreign molecules. Very recently, Fontana et al. ([@B1]) showed that VLPs containing glycoprotein of RABV are very efficient in induction of antibody mediated immune responses in Balb/c mice. Qi et al. ([@B7]) combined all these novel strategies, in order to develop an effective RABV vaccine. In present report, Qi and colleagues constructed chimeric RABV-like particles (cRVLPs) containing RABV glycoprotein and matrix protein, expressing membrane-anchored flagellin or E. coli heat-labile enterotoxin B (LTB). Immunological studies in BALB/c mice and dog models demonstrated that both humoral and cellular immune responses were stronger with cRVLPs, compared with standard rabies VLPs (sVLPs). Further, Qi et al. ([@B7]) suggest that flagellin promote antigen processing and presentation by inducing higher expression of MHC I and II on the surface of DCs. Interestingly, in a pioneer study, mucosal delivery of inactivated influenza vaccine have been shown to induce heterotypic immunity against H1N1 virus, when administered with heat-labile enterotoxin B (Tumpey et al., [@B8]). These attributes make flagellin and enterotoxin B outstanding adjuvants for use in vaccines.

In conclusion, present and previous reports suggest that chimeric VLPs are novel class of subunit vaccines and possess capability to induce both protective innate and adaptive immune responses. Possibly, use of immuno-modulators along with cRVLPS may enhance the efficacy of existing rabies vaccines. Further, detailed mechanism of the comprehensive effect of flagellin and enterotoxin B stimulated T and B-cells, on antiviral immune responses, should be investigated.
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